Teza Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,434	Closed	-$306K	–	213
2025 Q2	$306K	Sell	2,434 -2,870	-54%	-$329K	0.23%	179
2025 Q1	$587K	Sell	5,304 -12,560	-70%	-$1.59M	0.27%	118
2024 Q4	$2.44M	Buy	17,864 +765	+4%	+$94.6K	0.37%	67
2024 Q3	$1.97M	Buy	17,099 +7,055	+70%	+$967K	0.22%	137
2024 Q2	$1.38M	Buy	10,044 +5,359	+114%	+$735K	0.17%	190
2024 Q1	$646K	Sell	4,685 -937	-17%	-$128K	0.09%	295
2023 Q4	$741K	Sell	5,622 -3,117	-36%	-$359K	0.12%	229
2023 Q3	$983K	Buy	+8,739	New	+$920K	0.16%	187
2023 Q1	–	Sell	-15,691	Closed	-$1.87M	–	642
2022 Q4	$1.87M	Buy	15,691 +11,039	+237%	+$1.29M	0.36%	66
2022 Q3	$494K	Buy	+4,652	New	+$472K	0.1%	285
2020 Q3	–	Sell	-6,527	Closed	-$796K	–	531
2020 Q2	$796K	Buy	6,527 +2,746	+73%	+$303K	0.18%	175
2020 Q1	$327K	Buy	3,781 +802	+27%	+$78.5K	1.04%	33
2019 Q4	$320K	Buy	+2,979	New	+$312K	0.09%	403
2017 Q2	–	Sell	-6,795	Closed	-$294K	–	241
2017 Q1	$294K	Buy	+6,795	New	+$291K	0.09%	352